Attorney's Docket No.: 15702-004001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

applicant: Victor Gurewich et al.

Art Unit : 1651

Serial No.: 10/826,826

Examiner: Unknown

Filed : April 16, 2004

Title : METHODS, I

: METHODS, DEVICES, AND COMPOSITIONS FOR LYSIS OF OCCLUSIVE

BLOOD CLOTS WHILE SPARING WOUND SEALING CLOTS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Copies of the references listed on the attached form PTO-1449 are enclosed.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 15702-004001.

Respectfully submitted,

Date: 10-25-2004

V. Peter Fasse Reg. No. 32,983

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20949493.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Depoe

Signature

Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449
PATE VICTORIED

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 15702-004001

Application No. 10/826,826

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Victor Gurewich et al.

Filing Date April 16, 2004

Applicant

Group Art Unit 1651

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,472,692	12/05/1995	Liu et al.	424	94.63	07/02/1993
	AB	5,626,841	05/06/1997	Gurewich	424	94.63	06/07/1994
-	AC	5,759,542	06/02/1998	Gurewich	424	94.64	08/05/1994
	AD	5,866,358	02/02/1999	Brandazza et al.	435	69.1	10/06/1989
	AE	6,364,893	04/02/2002	Sahatjian et al.	606	194	08/05/1998
	AF	6,409,716	06/25/2002	Sahatjian et al.	604	509	10/07/1997

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AG							

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	AH	Gurewich et al., "Effective and Fibrin-specific Clot Lysis by a Zymogen Precursor Form of			
	All	Urokinase (Pro-urokinase)", J. Clin. Invest., Vol. 73, pages 1731-1739 (1984).			
	AI	Heckel et al., "Prediction of the three-dimensional structure of the enzymatic domain of t-PA",			
	Ai	J. Comp. Aided Mol. Des., Vol. 2, pages 7-14 (1988).			
		Liu et al., "A Comparative Study of the Promotion of Tissue Plasminogen Activator and Pro-			
	AJ	Urokinase-induced Plasminogen Activation by Fragments D and E-2 of Fibrin", J. Clin. Invest.,			
		Vol. 88, pages 2012-2017 (1991).			
	AK	Liu et al., "Inactivation of the Intrinsic Activity of Pro-urokinase by Diisoprophyl Fluorophosphate			
	711	Is Reversible", The Journal of Biological Chemistry, Vol. 270(15), pages 8408-8410 (1995).			
	AL	Liu et al., "Fragment E-2 from Fibrin Substantially Enhances Pro-urokinase-Induced Glu-			
		Plasminogen Activation. A Kinetic Study Using the Plasmin-Resistant Mutant Pro-urokinase Ala-			
		158-rpro-UK", Biochemistry, Vol. 31, pages 6311-6317 (1992).			
	AM	Liu et al., Prourokinase Mutant That Induces Highly Effective Cost Lysis Without Interfering With			
	7 1117	Hemostatsis", Circulation Research, Vol. 90, pages 757-763 (2002).			
	AN	Liu et al., "A Site-Directed Mutagenesis of Pro-Urokinase at the Flexiblr Loop Region of Active			
		Domain", Advances in Gene Technology: Protein Engineering and Beyond, (Abstract Only			
	AO	Nienaber et al., "Conformational Similarities between One-Chain and Two-Chain Tissue			
		Plasminogen Activator (t-PA): Implications to the Activation Mechanism on One-Chain t-PA",			
		Biochemistry, Vol. 31, pages 3852-3861 (1992).			
		Orsini et al., "Efficient renaturation and fibrinolytic properties of prourokinase and a deletion			
	AP	mutant expressed in Escherichia coli as inclusion bodies", Eur. J. Biochem., Vol 195, pages. 691-			
		697 (1991).			

Examiner Signature	Date Considered				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with					
next communication to applicant.					

Substitute Form PTO-1449 Attorney's Docket No. Application No. U.S. Department of Commerce Patent and Trademark Office 15702-004001 10/826,826 Applicant Information Disclosure Statement Victor Gurewich et al. by Applicant (Use several sheets if necessary) Filing Date Group Art Unit April 16, 2004 1651 (37 CFR §1.98(b))

(Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document				
	AQ	Pannell et al., "Activation of Plasminogen by Single-Chain Urokinase or by Two-chain Urokinase – A Demonstration That Single-Chain Has a Low Catalytic Activity (Pro-Urokinase)", Blood, Vol. 69(1), pages 22-26 (1987).				
	AR	Peterson et al., "Quenching of the Amidolytic Activity of One-Chain Tissue-Type Plasminogen Activator by Mutation of Lysine-416", Biochem., Vol. 29, pages 3451-3457 (1990).				
	AS	Verde et al., "Identification and primary sequence of an unspliced human urokinase poly(A) ⁺ RNA", Proc. Natl. Acad. Sci., Vol. 81, pages 4727-4731 (1984).				

Examiner Signature	Date Considered					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with						
next communication to applicant.						